My research interests center around identifying non-genetic mechanisms underlying resistance to targeted therapies with the goal of translating these findings into novel clinical treatments. Specifically, I aim to identify how drug-induced epigenetic and transcriptional rewiring drives acquired resistance to tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLCs). I am also investigating how co-opting anti-viral defense pathways overcomes resistance to TEAD inhibitors through co-blockade of EZH2 in Malignant Pleural Mesotheliomas. Upon securing a tenure-track Assistant Professor position, my long-term career goal is to integrate these findings and unearth their implications in immunotherapy resistance.